Advisors Preferred’s Enanta Pharmaceuticals ENTA Stock Holding History

Advisors Preferred’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-282	Closed	-$23K	–	223
2018 Q1	$23K	Buy	+282	New	+$21.7K	0.01%	208

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Advisors Preferred's ENTA Position: Q2 2018 in Review

Advisors Preferred sold out of Enanta Pharmaceuticals (ENTA) in Q2 2018, closing a stake of 282 shares — an estimated $23K sold.

Advisors Preferred first reported a position in ENTA in Q1 2018 and held it in 1 quarter. The position peaked at $23K in Q1 2018. 193 funds tracked by Wall St. Rank hold ENTA as of Q2 2018.

Advisors Preferred reported no remaining Enanta Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Advisors Preferred sold 282 Enanta Pharmaceuticals shares in Q2 2018, an estimated $23K.
Advisors Preferred first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 1 quarter.
Advisors Preferred's Enanta Pharmaceuticals position peaked at $23K in Q1 2018.
193 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2018.

Based on Advisors Preferred's 13F filing for Q2 2018, filed 7 Aug 2018.